Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-147 in APOL1-mediated Proteinuric Kidney Disease
NCT05312879Phase 3Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2022
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of inaxaplin in proteinuric kidney disease, sponsored by Vertex Pharmaceuticals. Started Mar 2022; status: active, not recruiting.
02
Drugs
inaxaplin
03
Conditions
proteinuric kidney disease
Beyond the preview
Go deeper on NCT05312879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05312879.